Table 3.
Characteristics of group receiving HCQ-AZ for at least 3 days and untreated group.
| Characteristics | Patient receiving HCQ-AZ ≥ 3 days N = 116 | Patient not receiving HCQ-AZ ≥ 3 days N = 110 | P-value | |
|---|---|---|---|---|
| Demographic factors (226)1 | ||||
| Gender | Female, n (%) | 70 (60.3) | 65 (59.1) | 0.85 |
| Male, n (%) | 46 (39.7) | 45 (40.9) | ||
| Age (years)2 | 50–85, n (%) | 66 (56.9) | 49 (44.5) | 0.07 |
| > 85, n (%) | 50 (43.1) | 61 (55.5) | ||
| Chronic conditions (159) | ||||
| Cardiovascular diseases | No, n (%) | 51 (62.2) | 49 (63.6) | 0.85 |
| Yes, n (%) | 31 (37.8) | 28 (36.4) | ||
| Hypertension | No, n (%) | 46 (56.1) | 50 (64.9) | 0.26 |
| Yes, n (%) | 36 (43.9) | 27 (35.1) | ||
| Dementia | No, n (%) | 61 (74.4) | 52 (67.5) | 0.34 |
| Yes, n (%) | 21 (25.6) | 25 (32.5) | ||
| Mental disorder | No, n (%) | 61 (74.4) | 59 (76.6) | 0.74 |
| Yes, n (%) | 21 (25.6) | 18 (23.4) | ||
| Diabetes mellitus | No, n (%) | 69 (84.1) | 65 (84.4) | 0.96 |
| Yes, n (%) | 13 (15.9) | 12 (15.6) | ||
| Chronic lung diseases | No, n (%) | 72 (87.8) | 68 (88.3) | 0.92 |
| Yes, n (%) | 10 (12.2) | 9 (11.7) | ||
| Stroke | No, n (%) | 69 (84.2) | 73 (94.8) | 0.04 |
| Yes, n (%) | 13 (15.8) | 4 (5.2) | ||
| Cancer | No, n (%) | 74 (90.2) | 70 (90.9) | 0.86 |
| Yes, n (%) | 8 (9.8) | 7 (9.1) | ||
| Chronic neurological disorder | No, n (%) | 76 (92.7) | 71 (92.2) | 0.9 |
| Yes, n (%) | 6 (7.3) | 6 (7.8) | ||
| Circumstances of diagnosis (226) | Case-by-case testing in patients with COVID-19 symptoms, n (%) | 23 (19.8) | 14 (12.7) | 0.1 |
| Mass testing, n (%) | 93 (80.2) | 96 (87.3) | ||
| Facility management of patients (226)3 | In LTCFs only | 0 (0) | 62 (56.4) | N/A |
| Other | 116 (100) | 48 (43.7) | ||
| Oxygen therapy (199) | No, n (%) | 79 (68.1) | 61 (73.5) | 0.4 |
| Yes, n (%) | 37 (31.9) | 22 (26.5) | ||
| Ceftriaxone or ertapenem therapy (199) | No, n (%) | 81 (69.8) | 55 (66.3) | 0.59 |
| Yes, n (%) | 35 (30.2) | 28 (33.7) | ||
| Low-molecular-weight heparin therapy (199) | No, n (%) | 98 (84.5) | 77 (92.8) | 0.08 |
| Yes, n (%) | 18 (15.5) | 6 (7.2) |
Abbreviations: HCQ, hydroxychloroquine; AZM, azithromycin; NA, Not applicable; LTCFs, long-term care facilities.
1
Number of individuals for whom data were available.
2
Median of the variable was used for analysis.
3
Indication of HCQ-AZ treatment was compulsorily administrated in coordination with hospital.